The Efficacy of Acarbose in the Treatment of Patients with Non–Insulin-Dependent Diabetes Mellitus: A Multicenter, Controlled Clinical Trial

Chiasson, Jean‐Louis; Josse, R G; Hunt, John A.; Palmason, Carol; Rodger, N. W.; Ross, Stuart A.; Ryan, Edmond A.; Tan, Meng H.; Wolever, T M

doi:10.7326/0003-4819-121-12-199412150-00004

Cited by 418 publications

(189 citation statements)

References 0 publications

Supporting

Mentioning

168

Contrasting

Unclassified

Order By: Relevance

“…In addition, the results are of interest because they illustrate how diabetic subjects interpret the dietary advice given to them by registered dietitians in major diabetes treatment centres in Canada. The present conclusion that acarbose therapy resulted in a small but statistically signi®cant weight loss appears to differ from the primary report of the results of this study, 2 where it was stated that body weight was`stable' during the 12 month study period on acarbose therapy (84.5 AE 1.2 kg at baseline to 84.2 AE 1.6 kg after 12 months). The reason for this is that body weight was not a primary or secondary endpoint of the study, and, thus, in our original paper, the data for body weight were not subjected to statistical analysis.…”

Section: Discussioncontrasting

confidence: 56%

“…The effect of acarbose on body weight becomes apparent when, as in this paper, the changes in weight from baseline are evaluated in the same way as the other ef®cacy variables. 2 The results of this study are not consistent with animal studies which suggest that, in some strains of rat, certain doses of acarbose reduce food intake. 5,6 The reason why acarbose should cause a reduction in food intake is unclear.…”

Section: Discussioncontrasting

confidence: 55%

“…The primary purpose of the study was to determine the effect of acarbose on blood glucose control and these results were reported elsewhere. 2 One of the secondary purposes of the study was to determine the effect of acarbose on nutrient intake. Subjects with NIDDM of at least six months duration with normal renal and liver function treated by diet alone, diet plus metformin, diet plus sulfonylurea or diet plus insulin were recruited from seven participating centers (Vancouver, Calgary, Edmonton, London, Toronto, Montreal and Halifax).…”

Section: Methodsmentioning

confidence: 99%

“…Hence, acarbose improves blood glucose control by reducing the rise of blood glucose after eating. 2,3 A potential advantage of acarbose is that, unlike sulfonylureas and insulin, 4 long-term use has been reported to result in weight loss. 3 The reason for this is not clear.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes

et al. 1997

View full text Add to dashboard Cite

OBJECTIVES: To see if the long-term treatment of non-insulin dependent diabetes (NIDDM) with the a a-glucosidase inhibitor acarbose affects food intake and body weight. DESIGN: Randomized, double-blind, placebo-controlled, parallel design clinical trial of 12 months duration. SUBJECTS: Subjects with NIDDM in four treatment strata: 77 on diet alone, 83 also treated with metformin, 103 also treated with sulfonylurea and 91 also treated with insulin. MEASUREMENTS: Two 3 day diet records were obtained before randomization to acarbose or placebo therapy, and additional 3 day diet records were obtained at 3, 6, 9 and 12 months after randomization. Body weight was also measured at these times. RESULTS: Of the 354 subjects randomized, 279 (79%) completed at least 9 months of therapy and, of these, 263 (94%) provided at least one diet record during the baseline period and two diet records during the treatment period. After one year, subjects on acarbose had lost 0.46 AE 0.28 kg, which differed signi®cantly from the 0.33 AE 0.25 kg weight gain on placebo (P 0.027). The difference in weight change between acarbose and placebo did not differ signi®cantly in the different treatment strata. Being in the study had signi®cant effects on diet, including a reduction in energy intake from 1760±1700 Kcal/d (P`0.05), a reduction in simple sugars intake from 18.5±17.4% of energy (P`0.001), and reductions in the number of different foods consumed (33±30, P`0.001) and the number of meals eaten per day (4.7± 4.3, P`0.001). However, compared to placebo treatment, acarbose had no effect on energy intake, nutrient intakes, or dietary patterns. CONCLUSIONS: In subjects with NIDDM on weight-maintaining diets, long-term acarbose therapy results in a small weight loss, but has no effect on energy or nutrient intakes. The weight loss induced by acarbose may be due partly to reduced doses of concomitant oral agents and insulin and partly to energy loss due to increased colonic fermentation.

show abstract

Section: Discussioncontrasting

confidence: 56%

Section: Discussioncontrasting

confidence: 55%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes

et al. 1997

View full text Add to dashboard Cite

show abstract

“…A dose diária máxima é de 300mg, embora seja referido o uso de até 600mg. Podem ser associadas a outro antidiabético oral ou insulina (15,20). Deve ser ressaltado que, em caso de hipoglicemia, recomenda-se à administração de glicose oral, uma vez que a sacarose não é absorvida.…”

Section: Inibidores Da Alfa-glicosidaseunclassified

Tratamento do diabetes mellitus do tipo 2: novas opções

Araújo

Britto

Cruz

2000

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

RESUMOO diabetes mellitus do tipo 2 (DM2) resulta de defeitos na secreção e ação da insulina. Ele está freqüentemente associado à resistência à insulina, obesidade andróide, dislipidemia e hipertensão arterial, constituindo a síndrome metabólica. O tratamento atual visa diminuir a resistência à insulina e melhorar a função da célula beta pancreática com dieta, exercícios, hipoglicemiantes orais, anti-hiperglicemiantes e/ou drogas anti-obesidade. Novas drogas no tratamento do DM estão surgindo, tornando possíveis múltiplas opções terapêuticas. Este artigo apresenta uma revisão sobre o assunto. ABSTRACTType 2 diabetes mellitus results from defects in both insulin action and insulin secretion. It is frequently associated with hyperinsulinemia, central obesity, dyslipidemia and arterial hypertension, components of the so-called metabolic syndrome. The main targets of the treatment are to decrease insulin resistance and improve beta cell function with diet, exercise, oral hypoglycemic and anti-hyperglycemic agents and/or anti-obesity drugs. New drugs for the treatment of diabetes mellitus make possible multiples therapeutics options. This article reviews this subject. O DIABETES MELLITUS DO TIPO 2 (DM2) ou não insulino-dependente e a intolerância à glicose têm se tornado um dos distúrbios mais comuns em clínica médica e estão freqüentemente associados à síndrome metabólica, que se caracteriza por resistência à insulina, obesidade andróide ou central, dislipidemia e hipertensão arterial (1,2). A síndrome metabólica é responsável pela maior morbi-mortalidade por doenças cardiovasculares tanto em obesos quanto em diabéticos tipo 2.O tratamento atual do DM2 visa manter o controle glicêmico adequado, seja com dieta hipocalórica, aumento da prática de exercícios físi-cos ou uso de medicações. Existem no momento diversas opções terapêu-ticas, que podem ser utilizadas isoladamente ou em associações: sensibilizadores da ação de insulina (metformina, tiazolidinedionas), anti-hiperglicemiantes (acarbosc), secretagogos (sulfoniluréias, repaglinida, nateglinida), drogas anti-obesidade e/ou insulina. O Diabetes Control and Complications Trial (DCCT) (3), um estudo prospectivo multicêntrico sobre as diversas formas de tratamento com insulina no DM1 e, mais recentemente,

show abstract

Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus

Salpeter¹,

Greyber²,

Pasternak³

et al. 2003

Arch Intern Med

263

View full text Add to dashboard Cite

show abstract

The Efficacy of Acarbose in the Treatment of Patients with Non–Insulin-Dependent Diabetes Mellitus: A Multicenter, Controlled Clinical Trial

Abstract: Acarbose improved long-term glycemic control in patients with non-insulin-dependent diabetes mellitus regardless of concomitant antidiabetic medication.

Cited by 418 publications

References 0 publications

Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes

Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes

Tratamento do diabetes mellitus do tipo 2: novas opções

Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus

Contact Info

Product

Resources

About